76 CHAPTER 3 Clinical benefit Patient Tumor type Start study treatment BOR PFS (weeks) Bi-allelic BRCA inactivation HRD-signature score Labeled indication as per 01-01-2021? 1 Cholangiocarcinoma 27 Jul 2018 SD 115.6 Yes 0.99 no 2 Castration resistant prostate cancer 16 Aug 2018 PR 72.1 Yes 1,00 yes 3 Hormone Receptor positive Breast cancer 30 Oct 2018 PR 67.3 Yes 1,00 yes 4 Renal cell carcinoma 21 Mar 2018 SD 46.9 yes 0.89 no 5 Ductal triple-negative breast cancer 13 Apr 2017 SD 45.1 Unknown Unknown yes 6 Castration resistant prostate cancer 24 Sep 2018 SD 40.7 no 0,00 yes 7 Castration resistant prostate cancer 28 Nov 2018 SD 40.1 Yes 0.88 yes 8 Castration resistant prostate cancer 23 Mar 2018 PR 38.6 Yes 0.94 yes 9 Castration resistant prostate cancer 25 Jan 2019 PR 36.6 Yes 0.98 yes 10 Castration resistant prostate cancer 17 Feb 2018 PR 36.6 Yes 0.99 yes 11 Castration resistant prostate cancer 09 Apr 2019 PR 32.1 Yes 0.98 yes 12 High Grade Serous Ovarian Cancer 15 May 2017 SD 31.6 Unknown Unknown yes 13 Cholangiocarcinoma 21 Aug 2018 SD 25.3 Yes 0.98 no
RkJQdWJsaXNoZXIy MTk4NDMw